
Chronic active BCR signaling is the key survival pathway in activated B-cell-like (ABC) DLBCL. In this project we will study how cytoskeleton dynamics influence BCR signaling and lymphoma cell survival. We will particularly focus on the GTPase RhoA which is recurrently mutated in DLBCL. In ABC-DLBCL cell lines and mouse models we will study i) the molecular function of mutant RhoA including its interplay with BCR signaling, ii) the role of mutant RhoA in lymphomagenesis, and iii) the possibilities to therapeutically target mutant RhoA signaling, particularly with regard to mechanisms of non-oncogene addiction induced by altered RhoA signaling.
PRINCIPAL INVESTIGATOR

Department of Medicine II
Hematology/Oncology
University Hospital Frankfurt
Theodor-Stern-Kai 7
60590 Frankfurt am Main
https://lymphoma-leukemia-research-frankfurt.de/
Project Interactions
-
A01
Using autochthonous mouse models of aggressive lymphoma to systematically distill actionable vulnerabilities
Prof. Dr. med. Hans Christian Reinhardt -
A03
LUBAC and its enzymatic activities in the development and therapy of ABC-diffuse large B-cell lymphoma
Prof. Dr. rer. nat. Henning Walczak, Dr. rer. nat. Gianmaria Liccardi -
A04
Role of apoptotic caspases in lymphomagenesis
Prof. Dr. rer. nat. Hamid Kashkar -
A05
Understanding the role of cFLIP in B cell lymphoma pathogenesis
Dr. rer. nat. Alessandro Annibaldi -
B01
LYN kinase as a key regulator in the microenvironmental niche of B cell lymphoid tumors
Prof. Dr. med. Michael Hallek, Dr. rer. nat. Phuong-Hien Nguyen